NCT03978507 is a NA clinical trial of Intelligent cueing in Parkinson Disease, sponsored by Tel-Aviv Sourasky Medical Center.

Who is sponsoring NCT03978507?

NCT03978507 is sponsored by Tel-Aviv Sourasky Medical Center.

What drugs are being tested in NCT03978507?

Interventions in NCT03978507: Intelligent cueing, Feedback about the number of steps.

What condition does NCT03978507 study?

NCT03978507 studies Parkinson Disease.

Is NCT03978507 still recruiting?

NCT03978507 is currently completed. Last updated 27 November 2023.

Last reviewed 2023-11-27 · How we verify

NCT03978507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Digital Wearable Walking Aid for Freezing of Gait in Parkinson´s Disease

Completed NA Last updated 27 November 2023

What this trial tests

NA trial testing Intelligent cueing in Parkinson Disease in 62 participants. Completed in 30 September 2023.

Timeline

13 June 2019

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	62
Start date	13 June 2019
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	2 locations across Belgium, Israel

Drugs / interventions tested

Intelligent cueing
Feedback about the number of steps

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 40 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate the effects of relatively long-term use of a wearable device that provides personalized and intelligent cues (e.g. only when FOG is detected) on FOG.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A machine learning contest enhances automated freezing of gait detection and reveals time-of-day effects.
Salomon A, Gazit E, Ginis P, Urazalinov B, et al · · 2024 · cited 19× · PMID 38844449 · DOI 10.1038/s41467-024-49027-0
Daily-Living Freezing of Gait as Quantified Using Wearables in People With Parkinson Disease: Comparison With Self-Report and Provocation Tests.
Denk D, Herman T, Zoetewei D, Ginis P, et al · · 2022 · cited 19× · PMID 36179090 · DOI 10.1093/ptj/pzac129
Protocol for the DeFOG trial: A randomized controlled trial on the effects of smartphone-based, on-demand cueing for freezing of gait in Parkinson's disease.
Zoetewei D, Herman T, Brozgol M, Ginis P, et al · · 2021 · cited 17× · PMID 34816053 · DOI 10.1016/j.conctc.2021.100817
Which Gait Tasks Produce Reliable Outcome Measures of Freezing of Gait in Parkinson's Disease?
Zoetewei D, Ginis P, Goris M, Gilat M, et al · · 2024 · cited 11× · PMID 39121137 · DOI 10.3233/jpd-240134

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03978507 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
Last refreshed: 27 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03978507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing